Effects of Oxytocin and Lorazepam on Fear-related Intra-amygdalar Activity
NCT ID: NCT03829839
Last Updated: 2019-04-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
120 participants
INTERVENTIONAL
2016-03-03
2017-08-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The hypothalamic peptide oxytocin (OXT) has anxiolytic effects both in healthy participants and patients with anxiety disorders by decreasing fear-associated amygdala activity. However, so far no human study has directly compared the underlying anxiolytic mechanisms of OXT and established anxiolytic agents on amygdala activity. Importantly, the amygdala is not a homogenous structure but rather consists of several subdivisions with structural and functional differences.
Therefore, the rationale of the present project is to determine the effects of intranasal OXT and the high-potency benzodiazepine lorazepam on fear-associated responses in intra-amygdalar subregions.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Exploring the Effects of Diazepam and Lorazepam
NCT00696033
Temporal Dynamics and Pharmacokinetics of Intranasally Administered Oxytocin
NCT03011970
Benzodiazepines for the Reduction of Distress and Pain During and After Emergency Department Care
NCT03756038
Effects of Oxytocin on Cognitive and Reactive Fear
NCT04292444
Dose-dependent Effects of Oxytocin on the Amygdala and Reward System
NCT03846739
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Oxytocin or PLC
Single dose of intranasal oxytocin (24 international units) or PLC.
Oxytocin
Intranasal administration, 24 international units (IU) oxytocin
Placebo nasalspray
The placebo nasalspray contain identical ingredients except for the active agent itself.
Lorazepam or PLC
Single dose of lorazepam (1mg) or PLC
Lorazepam 1 mg
Oral administration of 1mg lorazepam
Placebo Oral Tablet
The placebo pill contain identical ingredients except for the active agent itself.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oxytocin
Intranasal administration, 24 international units (IU) oxytocin
Lorazepam 1 mg
Oral administration of 1mg lorazepam
Placebo nasalspray
The placebo nasalspray contain identical ingredients except for the active agent itself.
Placebo Oral Tablet
The placebo pill contain identical ingredients except for the active agent itself.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* right-handed
Exclusion Criteria
* Current or past physical illness
* Psychoactive medication
* Sedative medication
* MRI contraindication (e.g. metal in body, claustrophobia)
18 Years
40 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Bonn
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Rene Hurlemann
Vice Chair of the Department of Psychiatry and Chair of the Medical Psychology Division
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Psychiatry, University of Bonn
Bonn, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LOXY
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.